New and Emerging Options in Osteoporosis: Improving Strategies and Outcomes in Practice

Preassessment

Please take this brief survey to share your experience and knowledge on obesity. Your input will help us as we prepare the program. The live event will take place Monday, March 19, 2018, from 6:00–9:00 PM PST at the McCormick Place South, Room S100A.

*
*
*
<10%10-25%25-50%50-75%>75%NA
Diabetes
Thyroid
Osteoporosis
Neuroendocrinology
Other
*
<10%10-25%25-50%50-75%>75%NA
Osteoporosis
Primary Hyperparathyroidism
Hypoparathyroidism
Chronic Kidney Disease
Other
*
<10%10-25%25-50%50-75%>75%NA
Postmenopausal
Postmenopausal (over 80)
Premenopausal
Male
Glucocorticoid-induced
Other secondary causes
*
<10%10-25%25-50%50-75%>75%NA
Feel that appropriate calcium and vitamin D are important to their overall skeletal
Feel that appropriate exercise is important to their overall skeletal health
Concerned in any way
Who would prefer not to use any pharmacological agent
*
YesNo
T-score < -2.5
T-score between -2.5 and -1.1
T-score > -1.0
Previous fragility fracture
Ongoing pharmacological therapy
*
Not at all concernedSlightly concernedSomewhat concernedModerately concernedExtremely concerned
Real and perceived side effects
Expense
Challenge to comply with dosing instructions
Perception of Efficacy
Other
*
Great resistanceSome resistanceLittle resistanceMinimal resistanceNo resistance
Oral bisphosphonates
Intravenous bisphosphonates
Anabolic drugs
Rank L inhibitors
Estrogen (in postmenopausal women)
*
*
AlwaysMost of the TimeOccasionallyRarelyThe guidelines are not very useful
Do you follow established guidelines for measurement of bone mineral density?
*